NYSE Euronext today announced the admission of IntegraGen, a pioneer in the development of molecular diagnostic tools, to NYSE Alternext.
IntegraGen is a major contender in clinical genomics, where it is developing a line of products and services for genetic diagnostic, the most dynamic segment of the in-vitro diagnostics market. The company offers clinical practitioners new diagnostic tools that favour the deployment of personalized treatment for complex illnesses in autism and oncology.
IntegraGen (ticker symbol: ALINT) was admitted to NYSE Alternext by direct listing of the 3,771,471 existing shares making up its capital. This followed the private placement with qualified investors of 800,149 new shares at a subscription price of €8.40 each, for a total €6.7 million.
Market capitalization of IntegraGen on the date of admission amounted to €31.7 million.
“We are very proud to welcome IntegraGen to NYSE Alternext and to accompany it in a new phase in its development, comments Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. Going public will enable IntegraGen to extend its reach and strengthen a drive fully supported by NYSE Euronext to promote early diagnosis of complex conditions such as autism.”
Bernard Courtieu, Chairman and Chief Executive of IntegraGen, adds: “We are delighted with the success of our listing on NYSE Alternext, which has raised €6.7 million from leading qualified investors. IntegraGen is now in a position to significantly accelerate the development of our molecular diagnostic products and services and their use by clinician, in order to satisfy unmet needs in the fields of oncology and autism. This new stage in our company’s growth will position IntegraGen as a benchmark in innovation, constantly working to improve patient care.”
NYSE Alternext today counts 141 listed companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Together they have raised over €2.3 billion, half of this through secondary issues, and their market capitalization totals €4.4 billion.